According to Weiss Healthcare's announcement, the cumulative deviation value of the company's stock price increase exceeded 30% for three consecutive trading days on December 31, 2025, January 5, and 6, 2026, which is an abnormal fluctuation. After self-inspection, the company had no obligation to disclose important matters, and production and operation were normal. By the end of 2025, new brain-computer interface products were in the early stages of market development, were not sold on a large scale, and their contribution to revenue was limited. In the first three quarters of 2025, the company's revenue was 326 million yuan, up 11.58% year on year; net profit was 102 million yuan, up 30.68% year on year. The company reminds investors to be aware of risks and invest prudently.

According to Weiss Healthcare's announcement, the cumulative deviation value of the company's stock price increase exceeded 30% for three consecutive trading days on December 31, 2025, January 5, and 6, 2026, which is an abnormal fluctuation. After self-inspection, the company had no obligation to disclose important matters, and production and operation were normal. By the end of 2025, new brain-computer interface products were in the early stages of market development, were not sold on a large scale, and their contribution to revenue was limited. In the first three quarters of 2025, the company's revenue was 326 million yuan, up 11.58% year on year; net profit was 102 million yuan, up 30.68% year on year. The company reminds investors to be aware of risks and invest prudently.